Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-08-23
2011-08-23
Sznaidman, Marcos (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C424S001690, C424S649000, C514S034000, C514S109000
Reexamination Certificate
active
08003630
ABSTRACT:
The present invention relates to pharmaceutical compositions for treating neoplasias in an animal or human comprised of a carrier and therapeutically effective amounts of at least one chemotherapeutic agent along with the biotherapeutic endogenous pentapeptide Met-enkephalin, referred to as opioid growth factor. Also provided are methods of treating neoplasias in an animal or human in need of such treatment, comprising the administration to the animal or human therapeutically effective amounts of a pharmaceutical composition comprised of a carrier and therapeutically effective amounts of at least one neoplasia-treating agent, such as a chemotherapeutic agent or radiation, along with opioid growth factor.
REFERENCES:
patent: 4537878 (1985-08-01), Plotnikoff
patent: 4757049 (1988-07-01), Plotnikoff
patent: 6136780 (2000-10-01), Zagon et al.
patent: 2007/0053838 (2007-03-01), Zagon et al.
Zagon et. al. , Cancer Letters (1997), 112:167-175.
Abbruzzese, Cancer (2002) 95:941-945.
Mosconi et. al. (European Journal of Cancer (1997) 33:S14-S17).
Abbruzzese (Cancer (2002) 95:941-945).
Zagon et. al. (Cancer Letters (1997) 112:167-175).
Jaglowski (Abstract, AAR, Control/Track No. 04-AB-5432-AACR, Nov. 7, 2003).
Goodman and Gilman's The Pharmacological Basis of Therapeutics (Tenth Edition (2001), McGraw Hill, Chapter I, pp. 3-29).
OPRS alerts (Jul. 2005).
Bisignani, Geoffrey J. et al., “Human Renal Cell Cancer Proliferation in Tissue Culture is Tonically Inhibited by Opioid Growth Factor”, The Journal of Urology—Abstract: vol. 102 (11) Dec. 1999.
Donahue, Renee N. et al., “Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis”, Am. J. Physiol. Regul. Integr. Comp. Physiol 296:R1716-1725, 2009.
Goldenberg, David et al., “Expression of Opioid Growth Factor (OGF)-OGF Receptor (OGFr) Axis in Human Nonmedullary Thyroid Cancer”, Thyroid, vol. 18, No. 11, 2008.
Hardman, J.G., Editor-in-chief, McGraw-Hill, “Goodman & Gilman's The Pharmacological Basis of Therapeutics”, Ninth Edition, US05/05268.
Hitt, R. et al., “Induction chemotherapy with paclitaxel, cisplatin and 5-fluorouracil for squamous cell carcinoma of the head and neck: long-term results of a phase II trial”, Annals of Oncology 13:1665-1673, 2002.
Jaglowski, Jeffrey R. et al., “Inhibition of human pancreatic cancer by gemcitablue is enhanced by the opioid growth factor (OGF): In vitro and in vivo studies”, Abstract, AAR, Control/Track No. 04-AB-5432-AACR, Nov. 7, 2003.
Jaglowski, Jeffrey R. et al., “Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck”, Cancer Chemother Pharmacol (2005) 56:97-104.
McLaughlin, Patricia J. et al., “Enhanced antitumor activity of paclitaxel on SCCHN with opioid growth factor (OGF): In vitro studies”, FASEB Journal, vol. 18, No. 4-5, 2004, Abstract. 649.7.
McLaughlin, Patricia J. et al., “Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of paclitaxel and opioid growth factor”, International Journal of Oncology 26: 809-816, 2005.
McLaughlin, Patricia J. et al., “Opioid growth factor (OGF) inhibits the progression of human squamous cell carcinoma of the head and neck transplanted in nude mice”, Cancer Letters 199 (2003) 209-217.
McLaughlin, Patricia J. et al., “Prevention and delay in progression of human squamous cell carcinoma of the head and neck in nude mice by stable overexpression of the opioid growth factor receptor”, International Journal of Oncology 33:751-757, 2008.
Zagon, Ian S. et al., “Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma”, Cancer Chemother Pharmacol (2005) 56:510-520.
Zagon, Ian S. et al., “Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation of diverse human cancers”, Am. J. Physiol Regul. Integr. Comp. Physiol 297: R000-R000, 2009.
Zagon, Ian S. et al., “Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells”, International Journal of Oncology, 30:775-783, 2007.
Zagon, Ian S. et al., “Prevention and delay in progression of human pancreatic cancer by stable overexpression of the opioid growth factor receptor”, International Journal of Oncology, 33:317-323, 2008.
European Search Report, PCT/US05/05268, The Penn State Research Foundation, Jul. 5, 2005.
Zagon et al., “Endogenous opioid systems regulate growth of neural tumor cells in culture”, Brain Research, 490:14-25 (1989). 1989 Elsevier Science Publishers B.V. (Biomedical Division).
McLaughlin Patricia J.
Smith Jill P.
Zagon Ian S.
McKee Voorhees & Sease, P.L.C.
Sznaidman Marcos
The Penn State Research Foundation
LandOfFree
Combinatorial therapies for the treatment of neoplasias... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combinatorial therapies for the treatment of neoplasias..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combinatorial therapies for the treatment of neoplasias... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2677521